AbCellera Biologics Inc. (ABCL) Q1 FY26 Earnings Call

ABCL635’s Q3 Phase II readout is the pivotal near-term test after favorable Phase I safety and target-engagement data.

Q1 FY26 results, source: company transcript and SEC filings
QuarterQ1 FY26
Call date2026-05-12
Length44 minutes
EPS$-0.14
EPS consensus$-0.22
Revenue$8.3M

What changed, guidance prior to now, analyst Q&A candor and the case for and against are part of Core.

All ABCL earnings · Back to ABCL overview

Transcript produced by Signals.AI from the company's own earnings call audio. Not personalized investment advice.